Hirudin biosimilar - Kerun BiopharmaceuticalAlternative Names: recombinant hirudin - Kerun Biopharmaceutical
Latest Information Update: 15 Apr 2016
At a glance
- Originator Kerun Biopharmaceutical
- Class Antithrombins; Hirudins
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Thrombosis